PharmNovo
Lund
About PharmNovo
PharmNovo's goal is to develop novel Delta Opioid Receptor Agonists that are safe and effective for chronic pain treatment (DORAs). This is a very different target than traditional opioid drugs, which have caused an epidemic of addiction and toxicity. The company addresses the significant unmet medical need for safe and effective chronic pain treatments, which affects up to 30% of the adult population in the United States and Europe.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Private
- Employees: 1 – 10
- Estimated revenue: $1K – $10K
- Total funding: $31.1M
- Last round: Series Unknown (Jul 2024)
- Website: pharmnovo.com
- Phone: +46 (0)705 44 32 50
Industries & Categories
Health Care, Pharmaceutical
Social Profiles
Canonical: https://fsome.com/organization/pharmnovo-119277 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.